top of page
.png)
Next Generation Customised therapies To Fight Cancer
Our Research Papers and Publications
Kumar C, Kohli S, Chiliveru S, Jain M, Sharan B* (2017). Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report. Clinical Case Reports 5(10):1692-1696
Kumar C, Kohli S, Chiliveru S, Bapsy PP, Jain M, Suresh Attili VS, Mohan J, Vaid AK, Sharan B*(2017).A retrospective analysis comparing APCEDEN® Dendritic Cell Immunotherapy with Best Supportive Care in refractory cancer. Immunotherapy 9(11):889-897
Kumar C, Kohli S, Bapsy PP, Vaid AK, Jain M, Attili VS, Sharan B*(2017)Immune modulation by dendritic-cell-based cancer vaccines. J. Biosci 42(1):161-173
Bapsy PP, Sharan B*, Kumar C, Das RP, Rangarajan B, Jain M, Suresh Attili VS, Subramanian S, Aggarwal S, Srivastava M, Vaid A (2014). Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy 16(2): 234-244
APCEDEN® Protocol & Clinician Handbook
Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy-
Chaitanya Kumar, Jasmine Bagga, Srikanth Chiliveru, Sakshi Kohli, Asmi Bharadwaj, Minish Jain, Shriram Inamdar & Bandana Sharan
Boosting Therapeutic Response By Outsmarting Tumor
Adjuvant based Immunotherapeutic Approaches to Enhance Patient Survival
Bandana Sharan (PhD), Srikanth Chiliveru (PhD), Jasmine Bagga (PhD), Sakshi Kohli (PhD), Asmi Bharadwaj (PharmD), Ashok K. Vaid (MBBS, MD, DM-Oncology), Chaitanya Kumar (MSc.)-Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN®)- Case report
bottom of page